brinzolamide/brimonidine (Rx)

Brand and Other Names:Simbrinza
  • Print

Dosing & Uses

AdultPediatric

Dosing Forms & Strengths

brinzolamide/brimonidine

ophthalmic suspension

  • 1%/0.2%

Glaucoma

Indicated for reduction of elevated intraocular pressure in patients with primary open-angle glaucoma

Instill 1 gtt in affected eye(s) TID

Ocular Hypertension

Indicated for reduction of elevated intraocular pressure in patients with ocular hypertension

Instill 1 gtt in affected eye(s) TID

Administration

Shake well before use

If more than 1 ophthalmic drop is administered, the drugs should be administered at least 5 minutes apart

Dosage Forms & Strengths

brinzolamide/brimonidine

ophthalmic suspension

  • 1%/0.2%

Glaucoma

Indicated for reduction of elevated intraocular pressure in patients with primary open-angle glaucoma

<2 years: Safety and efficacy not established

≥2 years: Instill 1 gtt in affected eye(s) TID

Ocular Hypertension

Indicated for reduction of elevated intraocular pressure in patients with ocular hypertension

<2 years: Safety and efficacy not established

≥2 years: Instill 1 gtt in affected eye(s) TID

Administration

Shake well before use

If more than 1 ophthalmic drop is administered, the drugs should be administered at least 5 minutes apart

Next:

Interactions

Interaction Checker

and brinzolamide/brimonidine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (8)

            • isocarboxazid

              isocarboxazid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.

            • linezolid

              linezolid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.

            • phenelzine

              phenelzine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.

            • procarbazine

              procarbazine, brimonidine. Mechanism: unknown. Contraindicated.

            • rasagiline

              rasagiline, brimonidine. Mechanism: unknown. Contraindicated. Brimonidine should not be used in patients receiving MAO inhibitors.

            • selegiline

              selegiline, brimonidine. Mechanism: unknown. Contraindicated. Coadministration is contraindicated.

            • selegiline transdermal

              selegiline transdermal, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.

            • tranylcypromine

              tranylcypromine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.

            Serious - Use Alternative (0)

              Monitor Closely (29)

              • amantadine

                brinzolamide will decrease the level or effect of amantadine by Other (see comment). Modify Therapy/Monitor Closely. Excretion rate of amantadine increases rapidly when urine is acidic, administration of urine acidifying drugs may increase elimination of amantadine from the body. Monitor for efficacy of amantadine.

              • amifostine

                amifostine, brimonidine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.

              • aspirin

                brinzolamide, aspirin. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • aspirin rectal

                brinzolamide, aspirin rectal. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • aspirin/citric acid/sodium bicarbonate

                brinzolamide, aspirin/citric acid/sodium bicarbonate. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • balsalazide

                brinzolamide, balsalazide. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • candesartan

                brimonidine increases effects of candesartan by pharmacodynamic synergism. Use Caution/Monitor.

              • choline magnesium trisalicylate

                brinzolamide, choline magnesium trisalicylate. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • diflunisal

                brinzolamide, diflunisal. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • digoxin

                brimonidine increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.

              • eprosartan

                brimonidine increases effects of eprosartan by pharmacodynamic synergism. Use Caution/Monitor.

              • esketamine intranasal

                esketamine intranasal, brimonidine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • irbesartan

                brimonidine increases effects of irbesartan by pharmacodynamic synergism. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, brimonidine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lisdexamfetamine

                brinzolamide will increase the level or effect of lisdexamfetamine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.

              • losartan

                brimonidine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.

              • lurasidone

                lurasidone, brimonidine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased sedation.

              • mesalamine

                brinzolamide, mesalamine. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • nitroglycerin rectal

                nitroglycerin rectal, brimonidine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .

              • olmesartan

                brimonidine increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor.

              • sacubitril/valsartan

                brimonidine increases effects of sacubitril/valsartan by pharmacodynamic synergism. Use Caution/Monitor.

              • salicylates (non-asa)

                brinzolamide, salicylates (non-asa). Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • salsalate

                brinzolamide, salsalate. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • stiripentol

                stiripentol, brimonidine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

              • sulfasalazine

                brinzolamide, sulfasalazine. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              • telmisartan

                brimonidine increases effects of telmisartan by pharmacodynamic synergism. Use Caution/Monitor.

              • topiramate

                topiramate, brinzolamide. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of kidney stone formation.

              • valsartan

                brimonidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.

              • willow bark

                brinzolamide, willow bark. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.

              Minor (150)

              • acebutolol

                brimonidine increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • alfentanil

                brimonidine increases effects of alfentanil by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • alfuzosin

                brimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.

              • alprazolam

                brimonidine increases effects of alprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • amiloride

                brimonidine increases effects of amiloride by pharmacodynamic synergism. Minor/Significance Unknown.

              • amitriptyline

                amitriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • amlodipine

                brimonidine increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • amobarbital

                brimonidine increases effects of amobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

                brinzolamide, amobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • amoxapine

                amoxapine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • butabarbital

                brinzolamide, butabarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • aripiprazole

                brimonidine increases effects of aripiprazole by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • asenapine

                brimonidine increases effects of asenapine by pharmacodynamic synergism. Minor/Significance Unknown.

              • atenolol

                brimonidine increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • azelastine

                brimonidine increases effects of azelastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • belladonna and opium

                brimonidine increases effects of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • benazepril

                brimonidine increases effects of benazepril by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • bendroflumethiazide

                brimonidine increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown.

              • benperidol

                brimonidine increases effects of benperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • betaxolol

                brimonidine increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • bisoprolol

                brimonidine increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • bosentan

                brimonidine increases effects of bosentan by pharmacodynamic synergism. Minor/Significance Unknown.

              • brompheniramine

                brimonidine increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • bumetanide

                brimonidine increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown.

              • buprenorphine

                brimonidine increases effects of buprenorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • buprenorphine buccal

                brimonidine increases effects of buprenorphine buccal by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • butabarbital

                brimonidine increases effects of butabarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • butalbital

                brimonidine increases effects of butalbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

                brinzolamide, butalbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • butorphanol

                brimonidine increases effects of butorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • ethotoin

                brinzolamide, ethotoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • captopril

                brimonidine increases effects of captopril by pharmacodynamic synergism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure.

              • carbinoxamine

                brimonidine increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • carvedilol

                brimonidine increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown.

              • celiprolol

                brimonidine increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • chloral hydrate

                brimonidine increases effects of chloral hydrate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • chlordiazepoxide

                brimonidine increases effects of chlordiazepoxide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • chlorothiazide

                brimonidine increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.

              • chlorpheniramine

                brimonidine increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • chlorpromazine

                brimonidine increases effects of chlorpromazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • chlorthalidone

                brimonidine increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown.

              • cinnarizine

                brimonidine increases effects of cinnarizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • clemastine

                brimonidine increases effects of clemastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • clevidipine

                brimonidine increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • clomipramine

                clomipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • clonazepam

                brimonidine increases effects of clonazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • clonidine

                brimonidine increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown.

              • clorazepate

                brimonidine increases effects of clorazepate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • clozapine

                brimonidine increases effects of clozapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • codeine

                brimonidine increases effects of codeine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • cyclizine

                brimonidine increases effects of cyclizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • cyclopenthiazide

                brimonidine increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown.

              • cyproheptadine

                brimonidine increases effects of cyproheptadine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • desipramine

                desipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • dexchlorpheniramine

                brimonidine increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • dexmedetomidine

                brimonidine increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • dextromoramide

                brimonidine increases effects of dextromoramide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • diamorphine

                brimonidine increases effects of diamorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • diazepam

                brimonidine increases effects of diazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • difenoxin hcl

                brimonidine increases effects of difenoxin hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • diltiazem

                brimonidine increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.

              • dimenhydrinate

                brimonidine increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • diphenhydramine

                brimonidine increases effects of diphenhydramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • diphenoxylate hcl

                brimonidine increases effects of diphenoxylate hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • dipipanone

                brimonidine increases effects of dipipanone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • doxazosin

                brimonidine increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown.

              • doxepin

                doxepin decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • doxylamine

                brimonidine increases effects of doxylamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • droperidol

                brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • drospirenone

                brimonidine increases effects of drospirenone by pharmacodynamic synergism. Minor/Significance Unknown.

              • enalapril

                brimonidine increases effects of enalapril by pharmacodynamic synergism. Minor/Significance Unknown.

              • eplerenone

                brimonidine increases effects of eplerenone by pharmacodynamic synergism. Minor/Significance Unknown.

              • epoprostenol

                brimonidine increases effects of epoprostenol by pharmacodynamic synergism. Minor/Significance Unknown.

              • esmolol

                brimonidine increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • estazolam

                brimonidine increases effects of estazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • ethacrynic acid

                brimonidine increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown.

              • ethanol

                brimonidine increases effects of ethanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • etomidate

                brimonidine increases effects of etomidate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • felodipine

                brimonidine increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • fenoldopam

                brimonidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              • fluphenazine

                brimonidine increases effects of fluphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • flurazepam

                brimonidine increases effects of flurazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • fosinopril

                brimonidine increases effects of fosinopril by pharmacodynamic synergism. Minor/Significance Unknown.

              • fosphenytoin

                brinzolamide, fosphenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • furosemide

                brimonidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.

              • guanfacine

                brimonidine increases effects of guanfacine by pharmacodynamic synergism. Minor/Significance Unknown.

              • haloperidol

                brimonidine increases effects of haloperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • hydralazine

                brimonidine increases effects of hydralazine by pharmacodynamic synergism. Minor/Significance Unknown.

              • hydrochlorothiazide

                brimonidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.

              • hydromorphone

                brimonidine increases effects of hydromorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • hydroxyzine

                brimonidine increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • iloperidone

                brimonidine increases effects of iloperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • iloprost

                brimonidine increases effects of iloprost by pharmacodynamic synergism. Minor/Significance Unknown.

              • imidapril

                brimonidine increases effects of imidapril by pharmacodynamic synergism. Minor/Significance Unknown.

              • imipramine

                imipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • indapamide

                brimonidine increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown.

              • isradipine

                brimonidine increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • ketanserin

                brimonidine increases effects of ketanserin by pharmacodynamic synergism. Minor/Significance Unknown.

              • labetalol

                brimonidine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

              • levorphanol

                brimonidine increases effects of levorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • lisinopril

                brimonidine increases effects of lisinopril by pharmacodynamic synergism. Minor/Significance Unknown.

              • lofepramine

                lofepramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • loprazolam

                brimonidine increases effects of loprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • lorazepam

                brimonidine increases effects of lorazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • lormetazepam

                brimonidine increases effects of lormetazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • loxapine

                brimonidine increases effects of loxapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • loxapine inhaled

                brimonidine increases effects of loxapine inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • maprotiline

                maprotiline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • mecamylamine

                brimonidine increases effects of mecamylamine by pharmacodynamic synergism. Minor/Significance Unknown.

              • meperidine

                brimonidine increases effects of meperidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • meprobamate

                brimonidine increases effects of meprobamate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • methadone

                brimonidine increases effects of methadone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • methyclothiazide

                brimonidine increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown.

              • metolazone

                brimonidine increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown.

              • metoprolol

                brimonidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • metyrosine

                brimonidine increases effects of metyrosine by pharmacodynamic synergism. Minor/Significance Unknown.

              • midazolam

                brimonidine increases effects of midazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • minoxidil

                brimonidine increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.

              • moexipril

                brimonidine increases effects of moexipril by pharmacodynamic synergism. Minor/Significance Unknown.

              • morphine

                brimonidine increases effects of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • moxisylyte

                brimonidine increases effects of moxisylyte by pharmacodynamic synergism. Minor/Significance Unknown.

              • moxonidine

                brimonidine increases effects of moxonidine by pharmacodynamic synergism. Minor/Significance Unknown.

              • nadolol

                brimonidine increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • nalbuphine

                brimonidine increases effects of nalbuphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • nebivolol

                brimonidine increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • nicardipine

                brimonidine increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • nifedipine

                brimonidine increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • nisoldipine

                brimonidine increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.

              • nortriptyline

                nortriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • olanzapine

                brimonidine increases effects of olanzapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • opium tincture

                brimonidine increases effects of opium tincture by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • oxazepam

                brimonidine increases effects of oxazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • oxycodone

                brimonidine increases effects of oxycodone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • oxymorphone

                brimonidine increases effects of oxymorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • paliperidone

                brimonidine increases effects of paliperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • papaveretum

                brimonidine increases effects of papaveretum by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • penbutolol

                brimonidine increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • pentazocine

                brimonidine increases effects of pentazocine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • pentobarbital

                brinzolamide, pentobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

                brimonidine increases effects of pentobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • perindopril

                brimonidine increases effects of perindopril by pharmacodynamic synergism. Minor/Significance Unknown.

              • phenobarbital

                brinzolamide, phenobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • perphenazine

                brimonidine increases effects of perphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • phenobarbital

                brimonidine increases effects of phenobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • phenoxybenzamine

                brimonidine increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor/Significance Unknown.

              • phentolamine

                brimonidine increases effects of phentolamine by pharmacodynamic synergism. Minor/Significance Unknown.

              • phenytoin

                brinzolamide, phenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              • pimozide

                brimonidine increases effects of pimozide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • pindolol

                brimonidine increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown.

              • prazosin

                brimonidine increases effects of prazosin by pharmacodynamic synergism. Minor/Significance Unknown.

              • primidone

                brinzolamide, primidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

                brimonidine increases effects of primidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • prochlorperazine

                brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • secobarbital

                brinzolamide, secobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia.

              Previous
              Next:

              Adverse Effects

              >10% (brimonidine)

              Somnolence in children (50-83%)

              Xerostomia (10-30%)

              Ocular hyperemia (10-30%)

              Burning and stinging (10-30%)

              Headache (10-30%)

              Blurring (10-30%)

              Foreign body sensation (10-30%)

              Fatigue/drowsiness (10-30%)

              Conjunctival follicles (10-30%)

              Ocular allergic reactions (10-30%)

              Ocular pruritus (10-30%)

              1-10% (brinzolamide)

              Blurred vision (5-10%)

              Dysgeusia (5-10%)

              Blepharitis (1-5%)

              Dermatitis (1-5%)

              Dry eye (1-5%)

              Foreign body sensation (1-5%)

              Headache (1-5%)

              Hyperemia (1-5%)

              Ocular discharge (1-5%)

              Ocular discomfort (1-5%)

              Ocular keratitis (1-5%)

              Ocular pain (1-5%)

              Ocular pruritus (1-5%)

              Rhinitis (1-5%)

              1-10% (brimonidine)

              Corneal staining/erosion (3-9%)

              Photophobia (3-9%)

              Eyelid erythema (3-9%)

              Ocular ache/pain (3-9%)

              Ocular dryness (3-9%)

              Tearing (3-9%)

              Upper respiratory symptoms (3-9%)

              Eyelid edema (3-9%)

              Conjunctival edema (3-9%)

              Dizziness (3-9%)

              Blepharitis (3-9%)

              Ocular (3-9%)

              Irritation (3-9%)

              Gastrointestinal symptoms (3-9%)

              Asthenia (3-9%)

              Conjunctival blanching (3-9%)

              Abnormal vision (3-9%) Muscular pain (3-9%)

              Lid crusting (<3%)

              Conjunctival hemorrhage (<3%)

              Abnormal taste (<3%)

              Insomnia (<3%)

              Conjunctival discharge (<3%)

              Depression (<3%)

              Hypertension (<3%)

              Anxiety (<3%)

              Palpitations/arrhythmias (<3%)

              Nasal dryness (<3%)

              Syncope (<3%)

              <1% (brinzolamide)

              Allergic reactions

              Alopecia

              Chest pain

              Conjunctivitis

              Diarrhea

              Diplopia

              Dizziness

              Dry mouth

              Dyspnea

              Dyspepsia

              Eye fatigue

              Hypertonia

              Keratoconjunctivitis

              Keratopathy

              Kidney pain

              Lid margin crusting or sticky sensation

              Nausea

              Pharyngitis

              Tearing

              Urticaria

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Neonates and infants (younger than 2 yr)

              Cautions

              Contains brinzolamide, a sulfonamide; caution with history of sulfonamide allergy

              Carbonic anhydrase activity observed in both the cytoplasm and around the plasma membranes of the corneal endothelium, and therefore there is an increased potential for developing corneal edema in patients with low endothelial cell counts

              Brinzolamide and its metabolite are excreted predominantly by the kidney and is not recommended in patients with severe renal impairment

              Not studied in patients with acute angle-closure glaucoma

              Contains benzalkonium chloride (preservative); remove contact lenses during instillation to avoid absorption by soft lenses (may reinsert 15 minutes after instillation)

              Brimonidine elicits <5% mean decrease in blood pressure 2 hr after instillation; caution with severe cardiovascular disease

              Not studied with severe hepatic impairment

              Brimonidine may potentiate syndromes associated with vascular insufficiency (eg, depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans)

              Bacterial keratitis reported from inadvertent contamination of multiple-dose containers of topical ophthalmics

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: C

              Lactation: Unknown whether distributed in human breast milk; do not breast feed

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Brinzolamide: Carbonic anhydrase inhibitor; inhibition of carbonic anhydrase in ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport

              Brimonidine: Alpha2 adrenergic receptor agonist; decreases aqueous humor secretion and increases uveoscleral outflow

              Absorption

              Peak plasma time: 1-4 hr (brimonidine)

              Peak plasma concentration: <10 ng/mL (brinzolamide)

              Distribution

              Protein bound: ~60% (brinzolamide)

              Due to its affinity for carbonic anhydrase (CA) II, brinzolamide distributes extensively into RBCs

              Metabolism

              Metabolized by liver (brimonidine)

              Metabolites: N-desethyl brinzolamide

              Elimination

              Half-life: 111 days (brinzolamide); 3 hr (brimonidine)

              Excretion: Predominantly in urine (brinzolamide); 87% urine (brimonidine)

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.